COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

This post hoc analysis of the COMPARZ study (pazopanib, n = 557; sunitinib, n = 553) supported similar efficacy of first-line pazopanib and first-line sunitinib treatment in advanced renal cell carcinoma. Patients who required dose modifications because of toxicity received higher cumulative doses w...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Genitourin Cancer
Hlavní autoři: Sternberg, Cora N., Motzer, Robert J., Hutson, Thomas E., Choueiri, Toni K., Kollmannsberger, Christian, Bjarnason, Georg A., Nathan, Paul, Porta, Camillo, Grünwald, Viktor, Dezzani, Luca, Han, Jackie, Tannir, Nizar M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7518515/
https://ncbi.nlm.nih.gov/pubmed/31601514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2019.01.015
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky